Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | CTSS | P25774 | 5/20 | 0.48 |
| ▸ | CTSK | P43235 | 4/20 | 0.48 |
| ▸ | CTSB | P07858 | 3/20 | 0.48 |
| ▸ | CTSL | P07711 | 2/20 | 0.48 |
| ▸ | PTPRB | P23467 | 3/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.45 |
| ▸ | CCKAR | P32238 | 2/20 | 0.45 |
| ▸ | CCKBR | P32239 | 2/20 | 0.45 |
| ▸ | BCL2 | P10415 | 1/20 | 0.44 |
| ▸ | AKT1 | P31749 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18996992 | 0.81 | HDAC8 (0.54) | HDAC8CTSSCTSKCTSBCTSL | |
| SCHEMBL4525858 | 0.80 | JAK2 (0.41) | — | |
| SCHEMBL3944495 | 0.79 | HDAC8 (0.72) | HDAC8CTSSCTSKCTSBCTSL | |
| SCHEMBL9610766 | 0.79 | HDAC8 (0.72) | HDAC8CTSSCTSKCTSBCTSL | |
| SCHEMBL3007610 | 0.78 | HDAC8 (0.63) | HDAC8CTSSCTSKCTSBCTSL | |
| SCHEMBL3007613 | 0.78 | HDAC8 (0.63) | HDAC8CTSSCTSKCTSBCTSL | |
| SCHEMBL4374376 | 0.78 | JAK2 (0.61) | HDAC8 | |
| SCHEMBL4374373 | 0.78 | JAK2 (0.61) | HDAC8 | |
| SCHEMBL4377740 | 0.78 | JAK2 (0.61) | HDAC8 | |
| SCHEMBL3667404 | 0.77 | HDAC8 (0.64) | HDAC8CTSSCTSKCTSBCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211919-B2 | Amide derivatives as rock inhibitors | ASTELLAS PHARMA INC. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-20090105231-A1 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2009-04-23 | — | — | US | disclosed |
| EP-1922306-A2 | AMIDE DERIVATIVES AS ROCK INHIBITORS | Astellas Pharma Inc. (JP) | 2008-05-21 | — | — | EP | disclosed |
| WO-2007026920-A2 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105231-A1 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ROCK1, ROCK2, RHOA | HDAC8 31/4885CTSS 2190/4885CTSK 1797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.